BioMarin To Present Data Showing Long-Term Benefit Of VOXZOGO On Growth In Children With Achondroplasia At 2023 European Society For Paediatric Endocrinology Meeting
Portfolio Pulse from Benzinga Newsdesk
BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) announced that new data on VOXZOGO® (vosoritide) in children with achondroplasia will be presented at the 61st Annual European Society for Paediatric Endocrinology (ESPE) Meeting. The data shows long-term benefits of VOXZOGO on growth in children with achondroplasia. The company is expecting label expansion decisions from U.S. and European Regulatory Authorities in Q4.
September 21, 2023 | 2:02 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
BioMarin's VOXZOGO shows long-term growth benefits in children with achondroplasia. Label expansion decisions are expected from U.S. and European Regulatory Authorities in Q4.
The new data on VOXZOGO's long-term benefits in children with achondroplasia is positive news for BioMarin. If the label expansion decisions from U.S. and European Regulatory Authorities are positive, it could lead to increased sales of VOXZOGO, positively impacting BioMarin's stock price.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100